The new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with €4.2m from mainly local investors, Augustine’s first priority is finding new therapeutics for patients suffering from Charcot-Marie-Tooth disease, a hereditary motor and sensory neuropathy of the peripheral nervous system.
British diagnostics play OBD lands contract with US pharma
Latest NewsThe technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic biomarker discovery and development platform causing a share price gain of 15%.
Iberian biotech newcomer
ProductsThe geographical proximity of Spain’s Northwestern region Galicia to Northern Portugal is a key factor for the birth of the new bioregion CT-Bio. This achievement looks forward to improving business competitiveness and the consolidation of the biotech and life sciences sector internationally.
Determined to grow
OpinionSpanish 3P Biopharmaceuticals has shown tremendous growth, at least 10 per cent above market growth rate in the past four years. European Biotechnology spoke with Dámaso Molero, CEO of the Spanish CDMO, about growth perspectives and future strategies.
Truffle’s BioMedTech fund filled with €250m
Latest NewsParis-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach.
Cellestia: €20m to get to Phase II
Latest NewsBasel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million.
Setting trends with eco-fashion
BackgroundEnzymes have been used widely for years to bleach textiles or shrink wool. However, the clothing sector is one of the world’s most polluting industries. And now fashion labels are turning increasingly to sustainable biofabrication and biotech-inspired methods to help lower the environmental footprint of their products.
Inceptua: Risen through the ranks
AppointmentsLuxembourg-based Inceptua has named Stefan Fraenkel as its new CEO. Fraenkel has been in charge of creating the Inceptua’s business unit Inceptua Pharma since 2017.
Biomarker identifies residual congestion in heart failure patients
Latest NewsData from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients.
Access instead of bureaucracy
OpinionA newly forming industry association warns the European Commission not to block patients’ access to the emerging EU market for medicinal cannabis. At the BIO-Europe in Hamburg, European Biotechnology spoke with one of the initiators, Peter Homberg.
Belgian start-up takes fight on neuropathies
Latest NewsThe new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with €4.2m from mainly local investors, Augustine’s first priority is finding new therapeutics for patients suffering from Charcot-Marie-Tooth disease, a hereditary motor and sensory neuropathy of the peripheral nervous system.